Skip to main content
. Author manuscript; available in PMC: 2013 Aug 31.
Published in final edited form as: Oncogene. 2012 Oct 8;32(35):4120–4129. doi: 10.1038/onc.2012.423

Figure 3. Relapse-free survival of 108 cases of human breast carcinoma dependent on LOH for hDMP1, INK4a/ARF, p53 or Hdm2 amplification.

Figure 3

Kaplan-Meier analyses have been conducted to study the impact for the impact of loss or gain of each locus on breast cancer patients’ disease-free survival up to 3,000 days. Only patients with stage I to III disease have been analyzed. Positive cases for gene deletion or amplification are indicated in solid lines and negative cases are shown in discontinuous lines. LOH for hDMP1 (a) has significantly positive impact (i.e. fair prognosis) on patient’s relapse-free survival while Hdm2 amplification (c) or LOH for p53 (d) had significantly negative impact. LOH for INK4a/ARF (b) had little influence on breast cancer patients’ long-term survival.